ScholarLens Back to search
2013•Chinese Journal of New Clinical MedicineRequires access

ERCC1:A new predictive genomic marker for chemotherapy of non-small cell lung cancer

Xian Le

Open publisher page 0 citations

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Surgery and chemotherapy are the main methods in therapy of NSCLC. The study and identification of predictive targeting molecules and markers of chemosensitivity of NSCLC will be beneficial to customized treatment of NSCLC patients. This article will review the research status about excision repair cross complementation group 1(ERCC1) as a predictive marker for chemotherapy of NSCLC.

About this research paper

What this paper is about

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Surgery and chemotherapy are the main methods in therapy of NSCLC. The study and identification of predictive targeting molecules and markers of chemosensitivity of NSCLC will be beneficial to customized treatment of NSCLC patients. This article will review the research status about excision repair cross complementation group 1(ERCC1) as a predictive marker for chemotherapy of NSCLC.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Surgery and chemotherapy are the main methods in therapy of NSCLC. The study and identification of predictive targeting molecules and markers of chemosensitivity of NSCLC will be beneficial to customized treatment of NSCLC patients. This article will review the research status about excision repair cross complementation group 1(ERCC1) as a predictive marker for chemotherapy of NSCLC.

Key concepts: ERCC1, Medicine, Oncology, Predictive marker, Lung cancer, Chemotherapy, Internal medicine, Cancer

Back to paper searchBrowse research topicsOriginal source
ERCC1:A new predictive genomic marker for chemotherapy of non-small cell lung cancer — Research Paper | ScholarLens